Dr. Wojciech Zareba from the University of Rochester refers to an ongoing NIH-sponsored trial of MTWA in MADIT-II patients.

"It is likely that SAECG and Microvolt T-Wave Alternans tests will emerge as routine for identifying low-risk and high-risk patients considered for ICD therapy."
Results from this study are expected to be forthcoming in late 2011.


This study has been enrolling for quite some time and we were very encouraged to see Dr. Zareba’s comments. Along with Dr. Arthur Moss, Dr. Zareba is part of a very well-respected team of researchers whose work has helped to establish many of the CRM guidelines in place today.